Novel long‐acting bronchodilators for COPD and asthma
Open Access
- 1 October 2008
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 155 (3), 291-299
- https://doi.org/10.1038/bjp.2008.284
Abstract
An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD) management and improving adherence with prescribed therapy is to reduce the dose frequency to the minimum necessary to maintain disease control. Therefore, the incorporation of once‐daily dose administration is an important strategy to improve adherence and is a regimen preferred by most patients, which may also lead to enhancement of compliance, and may have advantages leading to improved overall clinical outcomes. Once‐daily β2‐agonists or ultra long‐acting β2‐agonists (LABAs) such as carmoterol, indacaterol, GSK‐159797, GSK‐597901, GSK‐159802, GSK‐642444 and GSK‐678007 are under development for the treatment of asthma and COPD. Also some new long‐acting antimuscarinic agents (LAMAs) such as aclidinium, LAS‐35201, GSK656398, GSK233705, NVA‐237 (glycopyrrolate) and OrM3 are under development. In any case, the current opinion is that it will be advantageous to develop inhalers containing combination of several classes of long‐acting bronchodilator drugs in an attempt to simplify treatment regimens as much as possible. Consequently, several options for once‐daily dual‐action ultra LABA+LAMA combination products are currently being evaluated. A different approach is to have a dimer molecule in which both pharmacologies are present (these molecules are known as M3 antagonist‐β2 agonist (MABA) bronchodilators). The advent of a successful MABA product will revolutionize the field and open the door for a new range of combination products. British Journal of Pharmacology (2008) 155, 291–299; doi:10.1038/bjp.2008.284; published online 7 July 2008This publication has 52 references indexed in Scilit:
- Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPDThorax, 2008
- Global strategy for asthma management and prevention: GINA executive summaryEuropean Respiratory Journal, 2008
- Tolerability of indacaterol, a novel once-daily β2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety studyAnnals of Allergy, Asthma & Immunology, 2007
- The discovery of long acting β2-adrenoreceptor agonistsBioorganic & Medicinal Chemistry Letters, 2007
- Ultra-Long-Acting ??2-Adrenoceptor AgonistsDrugs, 2007
- Corticosteroids and adrenoceptor agonists: The compliments for combination therapy in chronic airways diseasesEuropean Journal of Pharmacology, 2006
- Ultra long-acting β2-agonists in development for asthma and chronic obstructive pulmonary diseaseExpert Opinion on Investigational Drugs, 2005
- Once-Daily Inhaled Corticosteroids in Mild to Moderate AsthmaDrugs, 1999
- Atypical molecular pharmacology of a new long-acting β2-adrenoceptor agonist, TA 2005European Journal of Pharmacology: Molecular Pharmacology, 1992
- Tracheal Relaxing Effects and β2-Selectivity of TA-2005, a Newly Developed Bronchodilating Agent, in Isolated Guinea Pig TissuesThe Japanese Journal of Pharmacology, 1991